TDP-43 suppresses CGG repeat-induced neurotoxicity through interactions with HnRNP A2/B1

Fang He1, Amy Krans1, Brian D Freibaum2

  • 1Department of Neurology, University of Michigan Medical School, 109 Zina Pitcher Pl, Ann Arbor, MI 48109, USA.

Insights

TAR DNA-binding protein (TDP-43) suppresses toxic CGG repeat expansions linked to Fragile X-associated tremor/ataxia syndrome (FXTAS). This protective effect involves interactions with hnRNP A2/B1, highlighting shared pathways in neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Nucleotide repeat expansions can cause neurodegeneration by sequestering RNA-binding proteins.
  • Mutations in RNA-binding proteins can also lead to neurodegeneration by altering RNA metabolism.
  • Fragile X-associated tremor/ataxia syndrome (FXTAS) involves CGG repeat expansions in the FMR1 gene, causing neurodegeneration.

Purpose of the Study:

  • To investigate the role of TAR DNA-binding protein (TDP-43) in suppressing CGG repeat-induced toxicity in a Drosophila model of FXTAS.
  • To elucidate the mechanism by which TDP-43 exerts its protective effects.

Main Methods:

  • Utilized a Drosophila model of FXTAS to study CGG repeat toxicity.
  • Examined the effects of TDP-43 and FUS co-expression on CGG repeat toxicity.
  • Investigated the role of TDP-43 mutations, RNA binding, and interactions with hnRNP A2/B1 homologues (Hrb87F, Hrb98DE) in the rescue mechanism.
  • Assessed the impact of TDP-43 on CGG repeat-triggered mis-splicing.

Main Results:

  • TDP-43 specifically suppressed CGG repeat-induced toxicity in Drosophila.
  • Disease-associated TDP-43 mutations abrogated this suppression.
  • TDP-43's RNA-binding ability was not required for rescue.
  • TDP-43-dependent rescue required interactions with fly hnRNP A2/B1 homologues.
  • TDP-43 suppressed CGG repeat-triggered mis-splicing of an hnRNP A2/B1-targeted transcript.

Conclusions:

  • TDP-43 acts as a suppressor of CGG repeat toxicity through interactions with hnRNP A2/B1.
  • These findings suggest a convergence of pathogenic mechanisms between repeat expansion disorders and neurodegenerative diseases involving RNA-binding proteins.
  • The study provides insights into potential therapeutic strategies targeting TDP-43 and hnRNP A2/B1 interactions.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
9.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81